The invention provides a population of placental-derived adherent cells that are CD10+, CD34-, CD105+, and CD200+ for use in a method for treatment of an individual having a disease or injury of the heart or circulatory system. Said placental-derived adherent cells may additionally be one or more of CD45-, CD90+, or OCT-4+.